146 terminated. 146 Phase 2, 46 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 146 | Terminated 146 |
| Phase 1 | 46 | Terminated 46 |
| Phase 3 | 5 | Terminated 5 |
Follow Precursor Cell Lymphoblastic Leukemia-Lymphoma: new trials by email Literature Review of Precursor Cell Lymphoblastic Leukemia-Lymphoma trials Research Report on Precursor Cell Lymphoblastic Leukemia-Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL CB-103, Venetoclax - Leukemia, Lymphoblastic, Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 2 | 2023-04-06 | 2025-11-26 |
| Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers Fludarabine, Cyclophosphamide, Thiotepa - Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 1 | 2022-10-06 | 2025-01-01 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma Relatlimab, Nivolumab - Lymphoma, Non-Hodgkin, Hodgkin Disease | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 5 | 2022-09-13 | 2026-06-26 |
| First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies 1A46 Injection - Non-Hodgkin's Lymphoma (disorder), Acute Lymphoid Leukemia, Disease (disorder) | Phase 1 / Phase 2 | Terminated | Chimagen Biosciences, Ltd | 7 | 2022-08-30 | 2025-02-13 |
| A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia Ponatinib, Venetoclax, Mini-hyper CVD - Acute Lymphoblastic Leukemia, Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2022-06-07 | 2026-04-27 |
| Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2022-02-17 | 2025-08-11 |
| First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) SAR443579 - Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory | Phase 1 / Phase 2 | Terminated | Sanofi | 101 | 2021-12-08 | 2026-07-06 |
| SPARK-ALL: Calaspargase Pegol in Adults With ALL Calaspargase pegol (S95015) - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Terminated | Institut de Recherches Internationales Servier | 42 | 2021-07-07 | 2026-10-29 |
| MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies MGTA-145, Plerixafor - Related Donors Donating PBSC to a Family Member, Healthy Donors | Phase 2 | Terminated | Ensoma | 7 | 2021-06-16 | 2024-11-06 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
| Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL Ponatinib 15 MG Oral Tablet - Acute Lymphoblastic Leukemia, Adult, Ph+ ALL | Phase 2 | Terminated | Institute of Hematology and Blood Transfusion, Czech Republic | 4 | 2021-02-16 | 2024-08-14 |
| ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT Blinatumomab - ALL, Childhood, Minimal Residual Disease | Phase 2 | Terminated | Prof. Christina Peters | 3 | 2020-12-17 | 2024-01-16 |
| Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL) Tisagenlecleucel - Acute Lymphoblastic Leukemia | Phase 2 | Terminated | Novartis Pharmaceuticals | 5 | 2020-10-19 | 2023-01-30 |
| GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL Cohort 1, GNR-084, Cohort 2, GNR-084, Cohort 3, GNR-084 - B-precursor Acute Lymphoblastic Leukemia, ALL | Phase 1 / Phase 2 | Terminated | AO GENERIUM | 14 | 2020-10-15 | 2026-09-21 |
| Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant blinatumomab - B-cell Adult Acute Lymphoblastic Leukemia, Stem Cell Leukemia | Phase 2 | Terminated | University of British Columbia | 8 | 2020-09-08 | 2022-02-21 |
| Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL) Asparaginase - Acute Lymphoblastic Leukemia | Phase 2 | Terminated | Gruppo Italiano Malattie EMatologiche dell'Adulto | 7 | 2020-06-25 | 2022-03-16 |
| Study of Sequential CAR-T Cell Treating Leukemia Children chimeric antigen receptor T cell - Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 2 | Terminated | Beijing Boren Hospital | 81 | 2020-05-01 | 2024-12-05 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors Idasanutlin, Venetoclax, Cyclophosphamide - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 38 | 2020-01-27 | 2024-12-20 |
| Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation Allogeneic Bone Marrow Transplantation, Bendamustine, Filgrastim-sndz - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 15 | 2019-10-28 | 2026-04-15 |
| Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Isatuximab, Dexamethasone or equivalent, Fludarabine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Terminated | Sanofi | 67 | 2019-08-06 | 2025-09-09 |
Showing 20 of 146. Sign in to see all of them.
Leukemia, Myeloid, Acute (63) · Leukemia (50) · Myelodysplastic Syndromes (47) · Lymphoma, Non-Hodgkin (44) · Leukemia, Lymphocytic, Chronic, B-Cell (38) · Burkitt Lymphoma (34) · Lymphoma (33) · Hodgkin Disease (32) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (29) · Lymphoma, Large B-Cell, Diffuse (28) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (26) · Lymphoma, Follicular (25) · Lymphoma, Mantle-Cell (25) · Multiple Myeloma (22)
Hemic and Lymphatic Diseases (146) · Immunoproliferative Disorders (145) · Neoplasms by Histologic Type (145) · Immune System Diseases (144) · Leukemia, Lymphoid (144) · Lymphatic Diseases (144) · Hematologic Diseases (142) · Lymphoproliferative Disorders (141) · Neoplasms (140) · Leukemia (96) · Pathological Conditions, Signs and Symptoms (73) · Pathologic Processes (72) · Leukemia, Myeloid (69) · Disease Attributes (67) · Bone Marrow Diseases (60)
Cyclophosphamide (37) · Methotrexate (26) · Cytarabine (21) · Rituximab (19) · fludarabine phosphate (17) · Dexamethasone (16) · fludarabine (16) · Tacrolimus (15) · Busulfan (14) · Vincristine (14) · Antilymphocyte Serum (13) · Filgrastim (13) · Mycophenolic Acid (13) · Calcium Dobesilate (12) · pegaspargase (12)
M.D. Anderson Cancer Center (16) · Fred Hutchinson Cancer Center (9) · Masonic Cancer Center, University of Minnesota (9) · National Cancer Institute (NCI) (9) · St. Jude Children's Research Hospital (5) · OHSU Knight Cancer Institute (4) · Sanofi (4) · Therapeutic Advances in Childhood Leukemia Consortium (4) · H. Lee Moffitt Cancer Center and Research Institute (3) · Washington University School of Medicine (3) · Bellicum Pharmaceuticals (2) · City of Hope Medical Center (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Medical College of Wisconsin (2) · Northside Hospital, Inc. (2)
United States (120) · France (14) · Italy (13) · Netherlands (10) · Germany (9) · United Kingdom (9) · Spain (7) · Canada (6) · Australia (5) · Belgium (5) · Austria (3) · Czechia (3) · Denmark (3) · South Korea (3) · Brazil (2)
Elias Jabbour (3) · Michael Burke, MD (2) · Scott R. Solomon, MD (2) · Sima Jeha, MD (2) · Stephen Ansell (2) · Steven C. Goldstein, MD (2) · Adam Petrich, MD (1) · Ajay Gopal (1) · Alan S Wayne, MD (1) · Allen R. Chen, MD,PhD. MHS (1) · Amer M Beitinjaneh, MD (1)
PMID 35622074, PMID 41671463, PMID 12011123, PMID 17579184, PMID 19139736, PMID 22766223, PMID 23233571, PMID 23426279, PMID 23782682, PMID 23949430, PMID 24241210, PMID 24355079, PMID 24891274, PMID 25441108, PMID 25878120, PMID 26053664, PMID 26432046, PMID 27505637, PMID 29296761, PMID 31217161, PMID 31969338, PMID 32692850, PMID 32959985, PMID 34343354, PMID 34376579, PMID 35007144, PMID 35750419, PMID 36841758, PMID 37863088, PMID 38207208, PMID 39563886, PMID 41043099, PMID 41074700, PMID 41331127, PMID 41379293
P30CA015704 (7), 2018 (4), 2008 (2), 2016 (2), 2023 (2), P30CA015083 (2), P30CA016058 (2), P30CA016672 (2), P50CA171963 (2), U10CA021115 (2), 2015 (1), N01CM00070 (1), N01CM17003 (1), N01CM62202 (1), P01CA018029 (1)